Search Results for "Insomnia"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Insomnia. Results 11 to 20 of 53 total matches.
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
pruritus,
dermatitis and pain, muscle
spasms, insomnia, abdominal
pain, constipation, diarrhea ...
View the Comparison Table: Drugs for Alzheimer's Disease
Cariprazine (Vraylar) for Adjunctive Treatment of Depression
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
, fatigue, nausea, insomnia, extrapyramidal
symptoms, and somnolence are common.
Dosage: 1.5 mg PO once ...
The FDA has approved the second-generation
antipsychotic drug cariprazine (Vraylar — Abbvie) for
adjunctive treatment of major depressive disorder
(MDD) in adults. Cariprazine was previously approved
for treatment of schizophrenia and bipolar depression,
and for acute treatment of manic or mixed episodes
associated with bipolar I disorder.
Med Lett Drugs Ther. 2023 May 29;65(1677):84-6 doi:10.58347/tml.2023.1677c | Show Introduction Hide Introduction
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
dementia.
Safety: Nasopharyngitis, urinary tract infection, dizziness, headache,
somnolence, insomnia ...
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be approved in the US
for this indication. It is also approved for treatment of
schizophrenia and as an adjunct to antidepressants for
treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101 doi:10.58347/tml.2023.1679b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2 doi:10.58347/tml.2023.1678c | Show Introduction Hide Introduction
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
such as headache,
constipation, nausea, insomnia, and injection-site
pain, erythema, and pruritus was similar ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
, and insomnia.
Impairment of cognition, attention,
concentration, and memory has also been
reported ...
View the Comparison Table: Some Drugs for Weight Management
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e127-30 doi:10.58347/tml.2025.1734b | Show Introduction Hide Introduction
Ashwagandha Supplements
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
of ashwagandha (Withania
somnifera) root extract in insomnia and anxiety: a double-blind,
randomized, placebo ...
Ashwagandha is an herb extracted from the roots of
an evergreen shrub (Withania somnifera) found in
India that has been used as a "tonic" for centuries.
No specific constituent has been identified as an
active ingredient. Herbal supplements containing
ashwagandha, which is also known as winter cherry
and Indian ginseng, are widely promoted now in the
US for treatment of pain, anxiety, stress, fatigue, sleep
disturbances, cognitive decline, diabetes, arthritis,
male infertility, and various cancers.
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
mouth, sexual
dysfunction, hyperhidrosis, anxiety, constipation,
decreased appetite, and insomnia ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Clonidine Oral Suspension (Onyda XR) for ADHD
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
hypotension, irritability, nightmares, insomnia,
constipation, and dry mouth. Rebound hypertension
can occur ...
The FDA has approved Onyda XR (Tris), an extended-release
(ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy
or as an adjunct to stimulant therapy for treatment
of attention-deficit/hyperactivity disorder (ADHD) in
children ≥6 years old. Clonidine ER tablets have been
available for years for treatment of ADHD in children
6-17 years old.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):205-6 doi:10.58347/tml.2024.1718d | Show Introduction Hide Introduction
Isatuximab (Sarclisa) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
, rash, infusionrelated
reactions, insomnia, and COVID-19 infection.
Neutropenia, secondary primary ...
Isatuximab-irfc (Sarclisa – Sanofi), a CD38-directed
cytolytic antibody, has been approved by the FDA for
treatment of newly diagnosed multiple myeloma in
adults who are not eligible for autologous stem cell
transplantation (ASCT). The drug was approved earlier
for treatment of relapsed or treatment-refractory
multiple myeloma.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e200-1 doi:10.58347/tml.2024.1717e | Show Introduction Hide Introduction